Sana Biotechnology
SANA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +149.7% in FY2025
Steven D. Harr, M.D. is the CEO of Sana Biotechnology and was paid $2.9M in FY2025 (Dec), down 67%.
Pay$100 in the stock at the end of FY21 → $26
Executives2
See all- 1Steven D. Harr, M.D.President, Chief Executive Officer, and DirectorFY2025
- 2Bernard J. CassidyFormer Executive Vice President, General Counsel, and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSana Biotechnology paid its 2 named executives $3.9M in total in FY2025 (Dec). CEO Steven D. Harr, M.D. was paid $2.9M of that.
| Name | |||
|---|---|---|---|
| Steven D. Harr, M.D.President, Chief Executive Officer, and Director | |||
| Bernard J. CassidyFormer Executive Vice President, General Counsel, and Corporate Secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Sana Biotechnology. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Hans BishopChair · 6 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Patrick Y. Yang, Ph.D.Director · 6 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Alise S. Reicin, M.D.Director · 4 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2024).
Shared directors
- Agilent TechnologiesHans Bishop1 shared
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 17, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
